BRD2 and ovarian carcinoma: We previously developed FSHR-mediated nanoparticles and found that FSH peptides on the surface of nanoparticles have the potential to selectively deliver paclitaxel to ovarian cancer cells expressing FSHR (Zhang et al., 2009; Fan et al., 2014).